Evusheld

Evusheld

Evusheld(衛冠盾,恩適得)由兩種全人源長效單克隆抗躰替沙格韋單抗(tixagevimab,AZD8895)和西加韋單抗(cilgavimab,AZD1061)的抗體組成,可以類比人體的天然抗體防禦機制,通過與新冠病毒刺突蛋白上的不同位點結合,降低病毒進入和感染健康細胞的能力,並有助於清除已被感染的細胞。 華盛頓大學醫學院的最新臨床前真實“活”病毒資料表明,Evusheld對現時主要流行病株

Price: Tel:

Tixagevimab and cilgavimab are two recombinant human IgG1 monoclonal antibodies with amino acid substitutions to extend antibody half-life (YTE), reduce antibody effector function, and minimize the potential risk of antibody-dependent enhancement of disease (TM). Tixagevimab and cilgavimab can simultaneously bind to non-overlapping regions of the receptor binding domain (RBD) of SARS-CoV-2 spike protein.


Dosage forms and strengths

Injection:

• tixagevimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial. 

• cilgavimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial.


The dosage of EVUSHELD for use is:

• Initial dose: 300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular injections. 

• Dosing for Individuals Who Initially Received 150 mg of Tixagevimab and 150 mg Cilgavimab

For individuals who initially received 150 mg tixagevimab and 150 mg cilgavimab:

• Initial dose ≤3 months prior: 150 mg tixagevimab and 150 mg cilgavimab.

• Initial dose >3 months prior: 300 mg tixagevimab and 300 mg cilgavimab.

• Repeat dose: 300 mg of tixagevimab and 300 mg of cilgavimab every 6 months. Repeat dosing should be timed from the date of the most recent EVUSHELD dose.